The ADDIKD guideline was developed by an expert clinician and academic volunteer working group using the GRADE approach of analysing available scientific and clinical evidence and accepted approaches in nephrology, clinical pharmacology, and cancer care. The guideline is targeted at clinicians. Patients, or other community members using these guidelines should do so in conjunction with a health professional. With the emergence of new evidence from the time of guideline development and publication, its content may not be considered as inclusive of all treatments or models of care. ADDIKD is not intended to be prescriptive, but to guide clinical decision-making where anticancer drugs will be used in patients with chronic kidney dysfunction. Patient care and treatment should always be based on the individual patient’s specific clinical circumstances and independent professional judgement of the treating clinical team. Cancer Institute NSW and eviQ assume no responsibility for any injury or damage to persons or property related to use of this information or any errors or omissions. Use is subject to eviQ’s disclaimer and copyright available at

Send feedback for this page

First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

17 Jun 2024